Disc Medicine (NASDAQ:IRON) Earns Buy Rating from Analysts at Stifel Nicolaus

Stock analysts at Stifel Nicolaus assumed coverage on shares of Disc Medicine (NASDAQ:IRON) in a report issued on Monday, Marketbeat Ratings reports. The firm set a “buy” rating and a $125.00 price target on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 44.98% from the stock’s previous close.

Several other equities analysts have also recently commented on IRON. Morgan Stanley boosted their target price on shares of Disc Medicine from $90.00 to $115.00 and gave the company an “overweight” rating in a research report on Thursday. Truist Financial started coverage on Disc Medicine in a report on Monday, July 21st. They set a “buy” rating and a $86.00 price target for the company. Raymond James Financial boosted their price target on Disc Medicine from $89.00 to $108.00 and gave the stock a “strong-buy” rating in a report on Friday, October 17th. National Bankshares set a $153.00 price target on Disc Medicine in a report on Friday, October 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Disc Medicine in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $116.30.

Disc Medicine Stock Performance

Shares of IRON stock opened at $86.22 on Monday. Disc Medicine has a one year low of $30.82 and a one year high of $95.95. The stock has a market cap of $3.00 billion, a P/E ratio of -19.29 and a beta of 0.79. The company has a fifty day moving average price of $69.07 and a two-hundred day moving average price of $58.32. The company has a debt-to-equity ratio of 0.05, a current ratio of 32.11 and a quick ratio of 32.11.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.41). As a group, equities analysts predict that Disc Medicine will post -4.07 EPS for the current year.

Insider Buying and Selling at Disc Medicine

In other Disc Medicine news, Director Kevin Bitterman sold 70,000 shares of the stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $88.91, for a total transaction of $6,223,700.00. Following the completion of the sale, the director directly owned 385,549 shares in the company, valued at approximately $34,279,161.59. This trade represents a 15.37% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold 218,441 shares of company stock worth $16,487,450 in the last ninety days. Corporate insiders own 3.64% of the company’s stock.

Institutional Trading of Disc Medicine

Large investors have recently made changes to their positions in the company. Amalgamated Bank grew its position in Disc Medicine by 38.6% in the 1st quarter. Amalgamated Bank now owns 787 shares of the company’s stock valued at $39,000 after purchasing an additional 219 shares during the period. Caitong International Asset Management Co. Ltd grew its position in Disc Medicine by 13,428.6% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 947 shares of the company’s stock valued at $47,000 after purchasing an additional 940 shares during the period. CWM LLC grew its holdings in shares of Disc Medicine by 213.5% during the second quarter. CWM LLC now owns 1,044 shares of the company’s stock valued at $55,000 after buying an additional 711 shares during the last quarter. Avanza Fonder AB acquired a new position in shares of Disc Medicine during the second quarter valued at about $57,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Disc Medicine by 15.6% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,338 shares of the company’s stock valued at $71,000 after buying an additional 181 shares during the last quarter. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.